Pharmafile Logo
Pharmafocus logo
Advanced Search
pliant

Novartis enters license agreement with Pliant Therapeutics for fibrosis assets

October 24, 2019
Research and Development

Novartis has signed a collaboration and license agreement with Pliant Therapeutics to develop and commercialise preclinical asset PLN-1474 which is …

News
alkermes

Alkermes to axe 160 jobs in cost-cutting restructure

October 24, 2019
Sales and Marketing

The Irish biopharma company expects to complete most of the job cuts by end of this year and will take …

News

Novartis receives EC label update approval for Cosentyx in ankylosing spondylitis

October 24, 2019
Research and Development

Novartis has announced that the European Commission has approved a label update for the up-titration of Cosentyx (secukunumab) to 300mg …

News
nhs_sign

Badly implemented electronic systems putting NHS patients at risk

October 24, 2019
Business Services

A new report has warned that poorly implemented electronic medication systems in the NHS could potentially lead to fatal medication …

News
gsk_l_rgb

GSK receives wider nod for Zejula as it competes with rival AstraZeneca

October 24, 2019
Research and Development

The US FDA has approved GlaxoSmithKline’s Zejula (niraparib) for the use in advanced ovarian, fallopian tube, or primary peritoneal cancer …

News
222170359

Damage control: How will pharma manage the health economic impacts of Brexit?

October 23, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HEOR, brexit, health economics and outcomes research, pharma

When it comes to life sciences and patient outcomes, the UK’s destiny is inextricably tied to its relationship with the …

Feature
vertex-headquarters

FDA approves Vertex’s Trikafta in new indication, now potentially covering 90% of cystic fibrosis patients

October 23, 2019
Research and Development, Sales and Marketing FDA, Trikafta, Vertex, cystic fibrosis, pharma

The FDA has granted marketing authorisation to Vertex’s Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF), it …

News

New study shows Prozac no better than placebo in treating autism

October 23, 2019
Research and Development

A small study has found that the commonly prescribed medication for kids and teenagers with autism is no more effective …

News
opdivo_1_1

BMS’ Opdivo+Yervoy+Chemo combo shows superior overall survival in first-line lung cancer

October 23, 2019
Research and Development Bristol-Myers Squibb, Cancer, NSCLC, Yervoy, lung cancer, opdivo, pharma

Bristol Myers Squibb has lifted the curtain on new Phase 3 data for its blockbuster immunotherapy Opdivo (nivolumab), showing that …

News
biogen_logo

Biogen aiming for Aducanumab to slow Alzheimer’s progression

October 23, 2019
Research and Development

US firm Biogen is hoping for approval to bring about a treatment that could slow the onset of Alzheimer’s disease. …

News
takeda_world

Takeda acquires investigational coeliac disease therapy

October 23, 2019
Research and Development

Takeda has acquired licensing for a first-in-class investigational coeliac disease therapy CNP-101/TAK-101. The Japanese pharma giant now has the rights …

News
shutterstock_159488225

Porton Biopharma signs potential $24m deal to push its intranasal anthrax vaccine into Phase 1 trials

October 22, 2019
Manufacturing and Production, Research and Development FDA, Porton Biopharma, anthrax, pharma

Porton Biopharma has signed a modification to its existing agreement with the US National Institute of Health’s National Institute of …

News

Novo Nordisk opens first Pharmatech branch office in Singapore

October 22, 2019
Manufacturing and Production Novo Nordisk, Singapore, pharma

Novo Nordisk has celebrated the launch of a new Pharmatech A/S branch office based in Singapore at a grand opening …

News
teva_copy

Teva offers massive $23 billion to avoid thousands of lawsuits

October 22, 2019
Manufacturing and Production

Israeli drug company Teva has said that it would offer $250 million in cash and a supply of Suboxone, an …

News
cruk_logo

Cancer Research UK announces push for earlier cancer detection

October 22, 2019
Manufacturing and Production

Cancer Research UK has embarked on a new international alliance with a plan to develop ‘radical new strategies’ and technologies …

News
vertex-headquarters

US FDA approves Vertex’s new breakthrough therapy for cystic fibrosis

October 22, 2019
Manufacturing and Production

The US FDA has approved Trikafta (elexacaftor/ivacaftor/tezacaftor) – the first triple combination therapy available for patients with most common cystic …

News
brexit-hintergrund_web

“No deal” Brexit and life sciences: What happens?

October 21, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, Europe, UK, brexit, no deal, no-deal, pharma

Prime Minister Boris Johnson may have agreed a withdrawal agreement with the European Union at the 11th hour, but despite …

Feature
alexion_sign

FDA approves Alexion’s Ultomiris in atypical haemolytic uremic syndrome for adults and children

October 21, 2019
Sales and Marketing Alexion, FDA, Ultomiris, pharma, rare disease

The FDA has moved to expand the existing label for Alexion’s Ultomiris (ravulizumab-cwvz) to include the treatment of atypical haemolytic …

News
ema_logo

CHMP recommends several drugs for EU market approval

October 21, 2019
Sales and Marketing

The EMA’s human medicines committee (CHMP) has recommended seven medicines for approval at its October 2019 meet including MSD’s Ervebo, …

News
rocheshanghai

Roche’s Tecentriq/Avastin combo smashes endpoints at Phase 3 in unresectable hepatocellular carcinoma

October 21, 2019
Research and Development, Sales and Marketing Cancer, Roche, immunotherapy, pharma, tecentriq

New Phase 3 data has emerged demonstrating the efficacy of Roche’s Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) in the …

News
The Gateway to Local Adoption Series

Latest content

Digital mental health technologies – a valuable tool in supporting people with depression and anxiety

January 29, 2026

Barts Health NHS Trust collaborates with H.I.G. Realty on healthcare innovation building

January 29, 2026

Rentschler Biopharma appoints Detra Glinatsis as Head of Business Development US

January 29, 2026

Five Facts about spinal muscular atrophy

January 28, 2026

Sobi’s Aspaveli receives European Commission approval for treatment of two rare kidney diseases

January 28, 2026